The Financial Toll Of Rare Diseases: How Treatment Costs Shape Innovation

Apart from affecting the health of patients, rare diseases also bring financial, emotional and social burdens. The total economic burden of rare diseases in the United States alone is nearly $1 trillion every year.

For families dealing with a family member diagnosed with a rare disease like peritoneal mesothelioma, the financial toll can be devastating. In this article, we’ll quickly explore the financial toll of rare diseases. We’ll also consider how treatment costs shape innovation.

IMAGE: UNSPLASH

Breaking Down The Financial Burden

The cost linked to rare diseases like peritoneal mesothelioma are categorized into:

Direct healthcare costs: These include hospitalizations, specialist visits, diagnostic testing, and prescription drugs.
Direct non-healthcare costs: These deal with transportation to treatment centers, medical equipment, and home modifications.
Indirect costs: These are lost income due to patients or caregivers leaving their jobs, early retirement, or reduced productivity.

Why Treatments Are Expensive

Rare conditions often require specialized therapies. These usually cost hundreds of thousands of dollars per patient each year. Patients also have to deal with what experts call a diagnostic odyssey. This involves years of testing, misdiagnoses, and specialist visits before a correct diagnosis is reached. This delay can drive costs higher. These are some of the key reasons why treatments are so expensive:

Limited expertise: A lot of primary care providers rarely encounter these conditions.
Multidisciplinary care: Patients usually need teams of oncologists, radiologists, geneticists, and more.
Orphan drugs: Treatments that are designed for very small patient groups come with high price tags.

How High Costs Spark Innovation

While these expenses are so high, they are driving new ways to healthcare financing such as:

Crowdfunding platforms like GoFundMe have become lifelines for patients and families. These platforms have helped people raise money they need for their treatments that aren’t covered by insurance.
Medical loan fintech startups are stepping in with specialized credit products. This allows patients to spread treatment costs over time in ways they cannot if they chose traditional lenders.
Insurance disruption is emerging with more providers experimenting with value-based care models. So, they reward treatments for their real-world outcomes instead of their development costs.

The cost of treating rare diseases has even led to frugal innovation. Certain healthcare providers now design lower-cost diagnostic and treatment solutions, which can be scaled efficiently. These innovative solutions are more common in underserved communities.

Startups And Tech In The Fight Against Financial Strain

Tech companies are doing a lot to reduce costs:

AI-based diagnostics are speeding up the identification of rare diseases and shortening the diagnostic odyssey. This, in turn, saves patients money in the long run.
Blockchain in healthcare payments is being tested to make billing more transparent. It can also reduce administrative costs.
Digital patient platforms connect people to clinical trials and financial aid resources. This makes healthcare more accessible.

Endnote

The financial toll of rare diseases affects patients, their families, healthcare systems, and economies at large. Yet, these challenges are pushing forward innovation. Rare diseases still remain difficult to treat, but their financial strain is rewriting the future of healthcare financing.